

# Dasatinib for treating Philadelphia-chromosome- positive acute lymphoblastic leukaemia (terminated appraisal)

Technology appraisal guidance

Published: 14 July 2021

[www.nice.org.uk/guidance/ta714](https://www.nice.org.uk/guidance/ta714)

# Contents

|                  |   |
|------------------|---|
| Advice.....      | 3 |
| Information..... | 3 |

## Advice

NICE is unable to make a recommendation about the use in the NHS of dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults because Bristol Myers Squibb does not intend to make a submission for the appraisal. Bristol Myers Squibb considers that there is not enough evidence to provide an evidence submission for this appraisal.

## Information

If NHS organisations wish to consider dasatinib for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4181-0